Company / Cash & Equivalents
Spero Therapeutics, Inc. Cash & Equivalents History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$40.3M
FY2025
5-year range
$40.3M / $112.6M
FY2021-FY2025
Trend
-23.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has declined for 4 consecutive years, from $113M in FY2021 to $40M in FY2025.
Based on SEC 10-K filings.
$40M in FY2025 with a 5-year CAGR of -13.9%.
Declined from $76M to $40M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -28.3%
- 5-Year CAGR
- -13.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- Spero Therapeutics, Inc.'s cash & equivalents has declined for 4 consecutive years.
- 5-year CAGR of -13.9%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 23.9% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $40.3M | -23.9% |
| FY2024 | $52.9M | -30.7% |
| FY2023 | $76.3M | -30.0% |
| FY2022 | $109.1M | -3.1% |
| FY2021 | $112.6M | +32.1% |
| FY2020 | $85.2M | +186.6% |
| FY2019 | $29.7M | -12.8% |
| FY2018 | $34.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026